Melanotan in a tropical country: tanning and safety questions

TL;DR

• Melanotan II is a cyclic laboratory-made peptide that can affect pigmentation-linked receptors, but its receptor activity does not answer every safety question.¹
• A pilot study with only three men observed increased pigmentation in two participants, while nausea and several effects unrelated to skin colour also appeared.²
• Reports involving severe toxicity, priapism, and changing moles are safety signals, yet single cases cannot show how often an event occurs or prove every suspected cause.³
• In a tropical setting, darker pigment is not a replacement for UV protection because a tan gives only limited defence against later skin damage.⁴

For Filipino readers, tanning sits inside a different daily backdrop from a short summer abroad. WHO notes that people in the tropics may need year-round UV protection, depending on skin type.⁵ That context can make “sunless tan” sound practical or even protective. The scientific record asks for more care. Pigment change, UV exposure, whole-body effects, mole changes, and product quality are separate questions.⁶

First, separate the name from the idea

Melanotan II, also called MT-II or MT-2, is a synthetic cyclic version of part of alpha-melanocyte-stimulating hormone.¹ That natural hormone family sends signals through melanocortin receptors.¹ One of them, MC1R, helps regulate melanin, the pigment that colours skin.¹ Melanotan II can also reach other melanocortin receptors, so its biology is not limited to colour change.¹

The Roman numeral matters.⁷ Melanotan I is a longer, linear molecule, while Melanotan II is a shorter, cyclic peptide.⁷ A paper about one cannot automatically support a claim about the other.⁷ “Melanotan” used alone may therefore hide an important identity check.⁷ Before reading any result, ask which molecule was tested and what the researchers measured.⁶

MT-2 Melanotan II is named here only as the neutral catalog reference below.¹

Tropical light changes the backdrop, not the evidence

For readers in the Philippines, tropical UV guidance matters beyond a single season.⁵ WHO says year-round protection may be needed, depending on skin type.⁵ The UV Index is the practical measure of radiation at a place and time.⁵ A higher number means greater potential harm to skin and eyes in less time.⁵

Heat and UV are not the same signal.⁵ Clouds can soften the brightness people notice while UV exposure still matters.⁵ Water, sand, and pale surfaces can also reflect radiation.⁵ These details help explain why a beach day, outdoor commute, or lunch-hour errand deserves a UV check without turning Filipino life into a warning label.⁵

The setting does not upgrade a peptide study.⁶ It simply makes the distinction between cosmetic pigment and sun protection more useful for local readers.⁶

What the early human study actually found

The first published human pilot was tiny.² It enrolled three healthy men in a single-blind, placebo-controlled design.² The participants received five alternating-day Melanotan II exposures during the study schedule.² Two had increased pigmentation one week after the study ended.²

The same record also noted effects far beyond colour.² Mild nausea appeared at most tested levels.² One participant had moderate sleepiness and fatigue at the highest level studied.² Stretching, yawning, and spontaneous erections also occurred.² These observations fit a peptide that reaches several melanocortin pathways rather than a pigment-only switch.¹

The result supports a narrow statement: pigmentation changed in two people under this protocol.² Three male volunteers cannot supply a dependable rate for benefits, side effects, or longer-term outcomes across a wider population.⁸

A tan is not wearable sunscreen

Pigment and protection are easy to blend into one mental shortcut.⁶ Yet US FDA guidance describes a UV-induced tan as a sign of skin damage.⁴ The extra melanin supplies only about SPF 2 to 4.⁴ That is not reliable protection from sunburn or other UV harm.⁴

WHO recommends checking the UV Index and using several barriers when protection is needed.⁵ Those barriers include shade, clothing, a broad-brimmed hat, sunglasses, and broad-spectrum sunscreen.⁵ Sunscreen should not be used to extend time in the sun.⁵

The key point is not that all pigment is identical.⁶ It is that a darker appearance does not answer the UV question.⁴ Any claim that moves from “more colour” to “safe in the sun” crosses an evidence boundary.⁶

Safety signals can come from other organs

A later controlled study shows why skin colour is only part of the picture.⁹ Ten men with erectile dysfunction joined a double-blind crossover comparison with placebo.⁹ Researchers recorded more erections and higher sexual-desire scores after Melanotan II.⁹ Nausea, stretching, and yawning were also more frequent.⁹ Four of nineteen Melanotan II exposures were linked with severe nausea.⁹

Case reports add different warnings, with different limits.¹⁰ One man developed agitation, sweating, rapid heart rate, muscle tremors, muscle breakdown, and kidney dysfunction after an exposure.¹⁰ Laboratory analysis confirmed Melanotan II in the sample.¹⁰ Another report described prolonged, painful erection that required surgery after earlier measures failed.¹¹

These cases matter as hazard signals.¹⁰ They do not tell us how common either event is, and they do not turn one patient’s course into everyone’s forecast.¹¹

Mole changes require careful language

Pigmented spots create one of the hardest interpretation problems.³ A dermatology review collected reports of existing moles becoming darker, new atypical moles appearing, and melanomas diagnosed during or soon after melanotan use.³ The review also said the reports did not establish a conclusive causal link.³

That qualification is essential.³ Some reported patients also had other melanoma risks, including fair skin, UV exposure, tanning-bed use, or family history.³ A diagnosis after an exposure does not by itself prove that the exposure caused it.³ At the same time, a darkening mole can become harder to judge visually, so the signal should not be waved away.³

The fair reading sits between panic and dismissal.³ Case reports identify events worth noticing, while controlled population research is needed to measure risk and separate possible causes.³

GHK-Cu is named here only as the neutral catalog reference below.

The label and the contents are another question

Even a perfectly read study cannot verify an untested item.¹² Researchers bought Melanotan II products from three online shops and checked them with chromatography and mass spectrometry.¹² Items described as containing 10 mg actually contained between 4.32 and 8.84 mg.¹² Samples from two shops also contained 4.1% to 5.9% unknown impurities.¹²

This small overseas sample does not describe other products or any Majiko catalog item.¹² Its value is conceptual: a label claim and measured composition can differ.¹² US FDA separately says compounded Melanotan II may carry immune-response risks for certain routes because peptides can aggregate or contain related impurities.¹³ The agency also says it lacks enough information to determine harm through those routes.¹³

Composition, sterility, storage, and route are product questions, not answers supplied by an early pigmentation paper.⁶

Bottom line

Tanning demand in a tropical country does not make the safety questions disappear.⁶ Melanotan II can affect pigmentation, but the first human pilot involved only three men.² Small controlled studies also recorded nausea, fatigue, yawning, and sexual effects.⁸ Case reports flag severe whole-body events and changing moles, while their design cannot establish frequency or certain causation.³ Separate testing found mismatches between labels and measured contents in a few online samples.¹² For Filipino readers, the sound approach is to keep five questions apart: identity, pigment, UV exposure, adverse events, and product composition.⁶ A darker appearance answers none of the others by itself.⁴

This article is educational research context, not medical advice. Catalog links are neutral references and do not imply a treatment or human-use recommendation.

Frequently asked questions

Are Melanotan I and Melanotan II the same?

No. They share a research history, but their structures differ.⁷ Melanotan I is a longer linear alpha-MSH analogue.⁷ Melanotan II is a shorter cyclic peptide built from the earlier scaffold.⁷ Results must stay attached to the exact molecule studied rather than the broad “melanotan” label.⁷

What did the first Melanotan II human study show?

The pilot enrolled three healthy men and observed increased pigmentation in two after the study schedule.² It also recorded nausea, fatigue, sleepiness, yawning, stretching, and spontaneous erections.² The sample was too small and narrow to provide broad rates or settle longer-term safety.⁸

Does darker skin from tanning prevent UV damage?

No tan should be treated as reliable sun protection.⁴ US FDA explains that extra melanin from a UV-induced tan provides only about SPF 2 to 4.⁴ WHO advises checking the UV Index and combining shade, clothing, hats, sunglasses, and broad-spectrum sunscreen when protection is needed.⁵

Do melanoma case reports prove that Melanotan II causes cancer?

No. A dermatology review described melanomas and changing moles during or after melanotan exposure, but it found no conclusive causal link.³ Other risk factors appeared in some reports.³ The cases are signals for attention, not a measured cancer rate or proof of a single cause.³

Why discuss nausea and erections in a tanning article?

They show that Melanotan II activity is not confined to pigment.¹ A small controlled study recorded nausea, yawning, stretching, erections, and higher sexual-desire scores.⁹ These findings help readers see why a cosmetic goal cannot be separated from effects involving other melanocortin pathways.¹

Can an online label confirm what a peptide product contains?

Not by itself. In one laboratory analysis, samples from three online shops contained less Melanotan II than their stated 10 mg, and some had unknown impurities.¹² The sample was small and overseas, so it cannot describe every product, seller, or catalog item.¹²

Sources

Footnotes

1. Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study.; Melanocortin 1 Receptor (MC1R): Pharmacological and Therapeutic Aspects.. Phase I human study and a pharmacology review describing the peptide and melanocortin receptor pathway. A mechanism description does not establish broad safety, a personal outcome, or the identity of a catalog item. ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶ ↩⁷ ↩⁸ ↩⁹

2. Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study.. Single-blind, placebo-controlled pilot study in three healthy male volunteers. The sample was extremely small, male-only, and designed for early safety and activity observations rather than population-wide conclusions. ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶ ↩⁷ ↩⁸ ↩⁹ ↩¹⁰ ↩¹¹ ↩¹² ↩¹³

3. Risks of unregulated use of alpha-melanocyte-stimulating hormone analogues: a review.. Review of case reports involving melanotan I or II and melanocytic changes. Case reports are signals with possible confounding from UV exposure, tanning-bed use, skin type, and other melanoma risk factors. ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶ ↩⁷ ↩⁸ ↩⁹ ↩¹⁰ ↩¹¹ ↩¹² ↩¹³ ↩¹⁴

4. Radiation: Protecting against skin cancer.; The Risks of Tanning.. WHO and US FDA public-health explanations of tanning and ultraviolet exposure. The statement concerns UV-induced tanning and should not be used to infer the quality or effect of a specific product. ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶ ↩⁷ ↩⁸

5. Radiation: Protecting against skin cancer.. Current WHO public-health guidance for ultraviolet exposure. This is global tropical guidance, not a measurement of UV exposure for a particular Philippine place, day, or person. ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶ ↩⁷ ↩⁸ ↩⁹ ↩¹⁰ ↩¹¹ ↩¹² ↩¹³

6. Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study.; Identification and characterization by LC-UV-MS/MS of melanotan II skin-tanning products sold illegally on the Internet.; Radiation: Protecting against skin cancer.; The Risks of Tanning.. Synthesis of the pilot pigmentation study, product analysis, and public-health UV guidance. This reading framework does not make a claim about a specific person's risk or a specific catalog product. ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶ ↩⁷ ↩⁸ ↩⁹ ↩¹⁰

7. Melanocortin 1 Receptor (MC1R): Pharmacological and Therapeutic Aspects.. Pharmacology review comparing the structures and development of melanotan I and II. Findings for one molecule cannot be silently reassigned to the other. ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶ ↩⁷ ↩⁸

8. Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study.; Effect of an alpha-melanocyte stimulating hormone analog on penile erection and sexual desire in men with organic erectile dysfunction.; Risks of unregulated use of alpha-melanocyte-stimulating hormone analogues: a review.. Synthesis of two small controlled human studies and a dermatology safety review. This is a bounded interpretation of study design, not a claim that no other study or record exists. ↩ ↩² ↩³

9. Effect of an alpha-melanocyte stimulating hormone analog on penile erection and sexual desire in men with organic erectile dysfunction.. Controlled crossover study in men with erectile dysfunction and organic risk factors. This small, selected clinical group does not estimate adverse-event frequency in a general population. ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶

10. Melanotan II injection resulting in systemic toxicity and rhabdomyolysis.. Single clinical toxicology case involving a 39-year-old man and chemical confirmation of the sample. A single case can flag a possible hazard but cannot estimate frequency or establish that every exposure has the same result. ↩ ↩² ↩³ ↩⁴

11. Melanotan Tanning Injection: A Rare Cause of Priapism.. Single urology case report. The report documents one event and cannot provide a population rate. ↩ ↩²

12. Identification and characterization by LC-UV-MS/MS of melanotan II skin-tanning products sold illegally on the Internet.. Laboratory analysis using liquid chromatography and mass spectrometry on samples from three online shops. This small overseas sample does not describe all products, any Philippine seller, or any catalog item. ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶ ↩⁷ ↩⁸ ↩⁹

13. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks.. Current US FDA compounding safety-risk record. This is a US regulatory assessment of compounded drugs and does not establish Philippine regulatory status. ↩ ↩²